New Standard of Care for Early dMMR/MSI-H Colorectal Cancer?

Another study shows good results with neoadjuvant immunotherapy in patients with locally advanced dMMR/MSI-H colorectal cancer, leading the authors to suggest it as a new standard of care.

Related Keywords

China , Wisconsin , United States , Chinese , Dustina Deming , , Collaborative Innovation Center , University Of Wisconsin Carbone Cancer Center , Journal Of The National Comprehensive Cancer Network , Sun Yat Sen University Cancer Center , Natural Science Foundation Of China , Key Laboratory Of Oncology , Guidelines Panel For Colon Rectal Anal Cancers , Chinese Society Of Clinical Oncology , Pei Rong Ding , State Key Laboratory , South China , Cancer Medicine , National Comprehensive Cancer , Wisconsin Carbone Cancer Center , Anal Cancers , Natural Science Foundation , Chinese Society , Natl Compr Canc , Colorectal Cancer , Cancer , Alignant Neoplasia , Arcinoma , Biologic Therapy , Colon Cancer , Alignant Colon Neoplasm , Malignant Rectal Neoplasm , Rectal Cancer , Ancer Rectal , Neoadjuvant , Monoclonal Antibody , Etuximab , Ituximab , Surgery , Immunotherapy , Adverse Effects , Side Effects , Chemotherapy , Postoperative , Tumor , Postoperative Complication , Patient Safety , Microsatellite Instability High , Microsatellite ,